- Ticker
- ACARIX.ST
- Price
- 0.59
- Stock movement up
- +0.03 (5.20%)
- Company name
- Acarix A/S
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Medical Devices
- Market cap
- 465.00M
- Ent value
- 412.21M
- Price/Sales
- 79.64
- Price/Book
- 5.49
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -29.00%
- 1 year return
- 22.91%
- 3 year return
- -26.07%
- 5 year return
- -16.62%
- 10 year return
- -
Last updated: 2024-07-23
DIVIDENDS
ACARIX.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 79.64 |
| Price to Book | 5.49 |
| EV to Sales | 70.60 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 792.16M |
| EPS (TTM) | -0.10 |
| FCF per share (TTM) | -0.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.84M |
| Gross profit (TTM) | 5.02M |
| Operating income (TTM) | -76.05M |
| Net income (TTM) | -76.29M |
| EPS (TTM) | -0.10 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 86.04% |
| Operating margin (TTM) | -1302.41% |
| Profit margin (TTM) | -1306.54% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 63.92M |
| Net receivables | 12.67M |
| Total current assets | 83.58M |
| Goodwill | 0.00 |
| Intangible assets | 11.83M |
| Property, plant and equipment | 216.00K |
| Total assets | 95.84M |
| Accounts payable | 1.62M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 11.14M |
| Total liabilities | 11.14M |
| Shareholder's equity | 84.70M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -79.19M |
| Capital expenditures (TTM) | 231.00K |
| Free cash flow (TTM) | -79.42M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -90.07% |
| Return on Assets | -79.60% |
| Return on Invested Capital | -90.07% |
| Cash Return on Invested Capital | -93.77% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.56 |
| Daily high | 0.59 |
| Daily low | 0.56 |
| Daily Volume | 5.54M |
| All-time high | 8.29 |
| 1y analyst estimate | 0.60 |
| Beta | 1.43 |
| EPS (TTM) | -0.10 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 22 Aug 2024 |
Downside potential
Loading...
Downside potential data
| ACARIX.ST | S&P500 | |
| Current price drop from All-time high | -92.92% | -1.81% |
| Highest price drop | -97.86% | -56.47% |
| Date of highest drop | 21 Dec 2023 | 9 Mar 2009 |
| Avg drop from high | -77.96% | -11.26% |
| Avg time to new high | 383 days | 12 days |
| Max time to new high | 1908 days | 1805 days |
COMPANY DETAILS
Marketcap
465.00M
Marketcap category
Small-cap
Description
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease (CAD) rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.
Employees
14
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that the Acarix shares (OTCQB: ACIXF) begin trading today on the OTCQB Market in the US. Acarix´s shares wi...
July 15, 2024
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the initiation of the first US-based clinical study to collect real-world data to compare workflows between traditional stres...
April 11, 2024
Acarix, a leader in acoustic-based Cardiac Diagnostics, is pleased to announce the results from a 2024 American College of Cardiology (ACC) poster presentation by Suzanne Baron, MD, MSc, Director of I...
April 8, 2024
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors to its team. Joining the advisory board are Ken Nelson, known for his leadership in the...
February 15, 2024
Acarix, a leader in advanced acoustic-based cardiac diagnostic devices today announces the CADScor® System has been added to the United States Federal Supply Schedule (FSS). The nationwide contract si...
February 5, 2024